Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Dose Titration of Subcutaneous Remodulin in Pulmonary Arterial Hypertension
2011-004631-31Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Primary endpoint: Safety and tolerability of rapid dose titration regimen of subcutaneous Remodulin. Started Feb 2012; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2011-004631-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004631-31.